Inhibition of Tumor Growth by Targeted Toxins in Mice is Dramatically Improved by Saponinum Album in a Synergistic Way

被引:36
作者
Bachran, Christopher [1 ]
Duerkop, Horst [2 ]
Sutherland, Mark [1 ]
Bachran, Diana [1 ]
Mueller, Christian [1 ]
Weng, Alexander [3 ]
Melzig, Matthias F. [3 ]
Fuchs, Hendrik [1 ]
机构
[1] Charite Univ Med Berlin, Zent Inst Lab Med & Pathobiolchem, D-12200 Berlin, Germany
[2] Charite Univ Med Berlin, Inst Pathol, D-12200 Berlin, Germany
[3] Free Univ Berlin, Inst Pharm Pharmazeut Biol, D-1000 Berlin, Germany
关键词
immunotoxin; saponin; epidermal growth factor; cancer; tumor model; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS-LYMPHOMA; T-CELL LYMPHOMA; DENILEUKIN DIFTITOX; FUSION-PROTEIN; RECOMBINANT IMMUNOTOXINS; GEMTUZUMAB OZOGAMICIN; ENHANCED CYTOTOXICITY; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY;
D O I
10.1097/CJI.0b013e3181ad4052
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The application of targeted toxins in cancer therapy remains a challenge due to the severe side effects as a consequence of the high systemic doses required. Here, we describe the combined application of a glycosylated triterpenoid (Spn) and epidermal growth factor receptor (EGFR)-targeted chimeric toxins (SA2E). The cytotoxicity of SA2E on murine TSA tumor cells transfected with human EGFR was enhanced 20,000-fold by low nonpermeabilizing Spn concentrations in a synergistic manner. Subcutaneous application of Spn and SA2E in BALB/c mice hearing a solid TSA cells transfected with epidermal growth factor receptor tumor resulted in 94% tumor volume reduction with a 50-fold lower chimeric toxin concentration compared with pure SA2E treatment. Side effects as monitored by observable complications, body weight, blood parameters: histologic analyses and antibody responses were only moderate and usually reversible.
引用
收藏
页码:713 / 725
页数:13
相关论文
共 41 条
[1]
REMOVAL OF ENDOTOXIN FROM PROTEIN SOLUTIONS BY PHASE-SEPARATION USING TRITON X-114 [J].
AIDA, Y ;
PABST, MJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 132 (02) :191-195
[2]
The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure [J].
Bachran, C ;
Sutherland, M ;
Heisler, I ;
Hebestreit, P ;
Melzig, MF ;
Fuchs, H .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2006, 231 (04) :412-420
[3]
Saponins in tumor therapy [J].
Bachran, Christopher ;
Bachran, Silke ;
Sutherland, Mark ;
Bachran, Diana ;
Fuchs, Hendrik .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (06) :575-584
[4]
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma [J].
Dang, Nam H. ;
Pro, Barbara ;
Hagemeister, Fredrick B. ;
Samaniego, Felipe ;
Jones, Dan ;
Samuels, Barry I. ;
Rodriguez, Maria A. ;
McLaughlin, Peter ;
Tong, Ann T. ;
Turturro, Francesco ;
Walker, Pamela L. ;
Fayad, Luis .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (03) :439-447
[5]
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®) [J].
Duvic, M ;
Kuzel, T ;
Olsen, EA ;
Martin, AG ;
Foss, FM ;
Kim, YH ;
Heald, PW ;
Bacha, P ;
Nichols, J ;
Liepa, A .
CLINICAL LYMPHOMA, 2002, 2 (04) :222-228
[6]
Recombinant immunotoxins for treating cancer [J].
FitzGerald, DJ ;
Kreitman, R ;
Wilson, W ;
Squires, D ;
Pastan, I .
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 293 (7-8) :577-582
[7]
The biological action of saponins in animal systems: a review [J].
Francis, G ;
Kerem, Z ;
Makkar, HPS ;
Becker, K .
BRITISH JOURNAL OF NUTRITION, 2002, 88 (06) :587-605
[8]
Frankel AE, 2003, CLIN CANCER RES, V9, P3555
[9]
A closer look at protein transduction domains as a tool in drug delivery [J].
Fuchs, H ;
Bachran, C ;
Heisler, I ;
Sutherland, M .
CURRENT NANOSCIENCE, 2005, 1 (02) :117-124
[10]
Targeted Tumor Therapies at a Glance [J].
Fuchs, H. ;
Bachran, C. .
CURRENT DRUG TARGETS, 2009, 10 (02) :89-93